Key Points
- Natera CEO Steven Leonard Chapman sold 3,076 shares for approximately $819,416 at an average price of $266.39, reducing his holdings by 2.99% to 99,897 shares. The sale occurred under a pre-arranged Rule 10b5-1 plan to cover tax withholding on vested equity awards.
- Natera shares opened at $274.58, near their 12-month high of $288.04, with the stock up significantly above its 50-day and 200-day moving averages. The company has a market capitalization of about $39.3 billion.
- Analysts maintain a generally positive view, with a consensus rating of “Moderate Buy” and an average price target of $267.83. Separately, Natera filed for Japanese approval of its Signatera bladder-cancer test, potentially expanding its international market opportunity.
Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider John Fesko sold 295 shares of the company's stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $267.99, for a total transaction of $79,057.05. Following the completion of the transaction, the insider owned 183,774 shares of the company's stock, valued at $49,249,594.26. This trade represents a 0.16% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
John Fesko also recently made the following trade(s):
- On Tuesday, July 28th, John Fesko sold 931 shares of Natera stock. The stock was sold at an average price of $254.07, for a total transaction of $236,539.17.
- On Monday, July 27th, John Fesko sold 782 shares of Natera stock. The shares were sold at an average price of $260.49, for a total transaction of $203,703.18.
- On Tuesday, May 26th, John Fesko sold 1,438 shares of Natera stock. The shares were sold at an average price of $202.84, for a total transaction of $291,683.92.
Natera Trading Down 0.2%
Shares of NASDAQ NTRA opened at $274.58 on Thursday. The firm has a market cap of $39.32 billion, a PE ratio of -168.45 and a beta of 1.51. Natera, Inc. has a 1-year low of $135.75 and a 1-year high of $288.04. The company has a fifty day moving average price of $251.03 and a 200 day moving average price of $222.85.
Wall Street Analysts Forecast Growth
Several research analysts have recently weighed in on NTRA shares. Sanford C. Bernstein assumed coverage on Natera in a research report on Friday, June 26th. They set an "outperform" rating and a $310.00 price objective for the company. Barclays cut their target price on Natera from $280.00 to $260.00 and set an "overweight" rating on the stock in a research note on Wednesday, June 24th. The Goldman Sachs Group assumed coverage on Natera in a research report on Friday, June 5th. They set a "neutral" rating and a $245.00 price target for the company. UBS Group set a $260.00 price target on shares of Natera in a research note on Wednesday, June 24th. Finally, Wolfe Research assumed coverage on shares of Natera in a report on Tuesday, June 2nd. They issued an "outperform" rating and a $260.00 price objective on the stock. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $267.83.
Check Out Our Latest Analysis on NTRA
Hedge Funds Weigh In On Natera
Several hedge funds have recently modified their holdings of the stock. Coatue Management LLC increased its position in shares of Natera by 1,446.1% in the fourth quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company's stock valued at $603,270,000 after acquiring an additional 2,463,008 shares during the last quarter. Wellington Management Group LLP raised its holdings in Natera by 94.7% during the fourth quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company's stock worth $1,140,026,000 after acquiring an additional 2,420,263 shares in the last quarter. Norges Bank acquired a new position in Natera during the fourth quarter valued at approximately $372,398,000. JPMorgan Chase & Co. grew its stake in Natera by 10.5% in the fourth quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company's stock valued at $2,944,800,000 after purchasing an additional 1,225,420 shares in the last quarter. Finally, AQR Capital Management LLC grew its stake in Natera by 39.0% in the third quarter. AQR Capital Management LLC now owns 2,400,065 shares of the medical research company's stock valued at $386,338,000 after purchasing an additional 673,315 shares in the last quarter. Institutional investors own 99.90% of the company's stock.
Key Natera News
Here are the key news stories impacting Natera this week:
- Positive Sentiment: Natera filed with Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for approval of its Signatera test for bladder cancer. Approval would expand the addressable market for the company’s molecular residual disease testing and could support additional international revenue growth. Natera Files for Japan PMDA Approval of Signatera Test in Bladder Cancer
- Neutral Sentiment: Natera reported sales by CEO Steven Leonard Chapman, CFO Michael Burkes Brophy, and executives Solomon Moshkevich and John Fesko totaling approximately 7,576 shares and $2.02 million. Each sale was executed under a pre-arranged Rule 10b5-1 plan and was made to cover tax withholding obligations from vested equity awards. The executives retained substantial positions, reducing the significance of the transactions as a signal of weakening confidence.
About Natera
(
Get Free Report)
Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.
Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
